The use of lithium is well established in bipolar disorders and the benefits are being
demonstrated in neurodegenerative disorders. Recently, our group showed that treatment …

A lower incidence of dementia in bipolar patients treated with lithium has been described.
This metal inhibits the phosphorylation of glycogen-synthase-kinase 3-α and β, which are …

The glycogen synthase kinase-3β (GSK3β) pathway plays a central role in Alzheimer's
disease (AD) and its deregulation accounts for many of the pathological hallmarks of AD …

Lithium has been shown to delay the progression of Alzheimer's disease to reduce the
prevalence of dementia. However, its narrow therapeutic index and numerous toxic effects at …

Background: Alzheimer's disease (AD) is a chronic neurodegenerative disorder with a
progressive loss of cognitive function. Currently, no effective treatment regimen is available …

Background: Microdose lithium is protective against Alzheimer's disease (AD), although the
precise mechanisms through which its protective effects are conferred remain unclear …

It was already shown that microdoses of lithium carbonate (Li 2 CO 3) promoted memory
stabilization in humans and mice. Prolonged treatment also reduced neuronal loss and …

Experimental data reveal that lithium is capable of attenuating Alzheimer's disease
pathology and stimulating adult hippocampal neurogenesis. Clinical studies show …

Epidemiological, preclinical, and clinical studies have suggested a role for microdose lithium
in reducing Alzheimer's disease (AD) risk by modulating key mechanisms associated with …

Background: There is a growing body of pre-clinical evidence suggesting that lithium (Li)
may protect neurons from a range of neurotoxic insults, hence the term neuroprotective …